References
- Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol 2001;45:265-315
- Konstas AGP, Holló G, Mikropoulos D, et al. Twenty-four hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in pseudoexfoliative glaucoma. Br J Ophthalmol 2010;94:209-13
- Konstas AGP, Mikropoulos DG, Embeslids TA, et al. 24-hour intraocular pressure with evening-dosed travoprost/timolol, compared with latanoprost/timolol in exfoliative glaucoma. Eye 2010;24:1606-13
- Konstas AGP, Holló G, Astakhov YS, et al. Factors associated with long-term progression or stability in exfoliation glaucoma. Arch Ophthalmol 2004;122:29-33
- Heil A, Bengtsson B, Hyman L, et al. Natural history of open-angle glaucoma. Ophthalmology 2009;116:2271-6
- Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007;144:533-40
- Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350-5
- Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol 2008;246:1593-601
- Rossi GC, Pasinetti GM, Scudeller L, et al. Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertensive patients. Eur J Ophthalmol 2012;23:296-302
- Holló G, Hommer A, Antón Lopez A, et al. Efficacy, safety and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients. J Ocul Pharmacol Therap 2014;30:468-75
- Konstas AG, Quaranta L, Katsanos A, et al. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol 2013;97:1510-15